Cagrilintide Research Peptide (AM833 / Long-Acting Amylin Analog)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Cagrilintide (AM833, NN9838, CAS 1415456-99-3) is a synthetic 37 amino acid long-acting acylated amylin analog developed by Novo Nordisk, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. Engineered as a dual amylin and calcitonin receptor agonist (DACRA), Cagrilintide incorporates five targeted structural modifications over native amylin — including N14E and V17R helix-stabilizing substitutions, three proline substitutions to reduce amyloid fibril formation, and an N-terminal C20 fatty diacid lipidation via a gamma-glutamic acid linker for albumin binding — producing an elimination half-life of approximately 159–195 hours in research models. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Compound Specifications
| Compound Name | Cagrilintide / AM833 / NN9838 |
| Classification | Long-acting acylated amylin analog / DACRA (Dual Amylin and Calcitonin Receptor Agonist) |
| Amino Acids | 37 |
| Receptor Targets | AMY1R, AMY2R, AMY3R (amylin receptors) + CTR (calcitonin receptor) |
| N-Terminal Modification | C20 eicosanedioic fatty diacid via gamma-glutamic acid linker — albumin binding |
| Key Substitutions | N14E, V17R (helix stabilization) + 25P, 28P, 29P (amyloid reduction) + C-terminal Pro (CTR potency) |
| Half-Life (Research Models) | ~159–195 hours (~7 days) |
| Molecular Formula | C₁₇₄H₂₇₁N₄₃O₅₁ (approximate) |
| Molecular Weight | ~3,900 g/mol (approximate) |
| CAS Number | 1415456-99-3 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| Synonyms | AM833, NN9838, Cagrilintide, long-acting DACRA |
Why Research Laboratories Select Cagrilintide
Cagrilintide is the most pharmacologically advanced long-acting amylin analog available for laboratory research — the only synthetic DACRA with published cryo-EM structural characterization across all four receptor subtypes (AMY1R, AMY2R, AMY3R, CTR), extensive Phase 2 and Phase 3 clinical trial literature, and a defined albumin-binding half-life extension mechanism. This combination of structural precision, receptor characterization depth, and clinical research literature makes it an unmatched reference tool for laboratories investigating amylin receptor pharmacology, neuroendocrine satiety signaling, and comparative incretin pathway biology.
- DACRA classification — non-selective agonist of AMY1R, AMY2R, AMY3R, and CTR simultaneously
- Cryo-EM characterized — structures published in Nature Communications (2025) across all four receptor subtypes
- N-terminal C20 fatty diacid lipidation — albumin binding half-life extension to ~7 days in research models
- Five structural modifications over native amylin — N14E/V17R helix stabilization + proline substitutions eliminating amyloid fibril propensity
- Active Phase 3 clinical development — CagriSema (Cagrilintide + Semaglutide) program by Novo Nordisk in Phase 3
- Studied alongside GLP-1 receptor agonists — CagriSema comparative receptor pathway biology reference compound
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
Cagrilintide was developed by Novo Nordisk through a systematic medicinal chemistry program. Kruse et al. (2021) published the development and SAR data in the Journal of Medicinal Chemistry. Fletcher et al. (2021) published receptor pharmacology comparative data in the Journal of Pharmacology and Experimental Therapeutics. Enebo et al. (2021) published Phase 2 data in The Lancet. Frias et al. (2023) published CagriSema Phase 2 data in The Lancet. Cryo-EM structural characterization across all four receptor subtypes was published in Nature Communications in 2025 (PMID: 40204768). Cagrilintide is not FDA approved for any indication. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: Kruse et al. (2021) — Journal of Medicinal Chemistry | Cryo-EM Structure (2025) — Nature Communications
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 7 days
- Avoid repeated freeze-thaw cycles to maintain peptide and lipidation integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Cagrilintide?
Cagrilintide (AM833, NN9838, CAS 1415456-99-3) is a synthetic 37 amino acid long-acting acylated amylin analog developed by Novo Nordisk. It is a non-selective DACRA — activating AMY1R, AMY2R, AMY3R, and CTR simultaneously — with an albumin-binding C20 fatty diacid modification producing a ~7-day half-life in research models. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
What is a DACRA?
DACRA stands for Dual Amylin and Calcitonin Receptor Agonist. Amylin receptors (AMY1R, AMY2R, AMY3R) are heterodimeric complexes formed by a calcitonin receptor (CTR) core combined with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3). Cagrilintide activates all four receptor complexes non-selectively, making it a pan-DACRA research reference compound distinct from selective amylin or calcitonin receptor agonists.
How does Cagrilintide differ from pramlintide?
Pramlintide (Symlin, FDA-approved) is a shorter-acting amylin analog derived from rat amylin sequence requiring multiple daily dosing protocols in research models (~20–48 minute half-life). Cagrilintide differs through N-terminal C20 fatty diacid lipidation for albumin binding, N14E/V17R helix-stabilizing substitutions, and three proline substitutions eliminating amyloid fibril propensity — producing a ~7-day half-life and CTR dual agonism classifying it as a DACRA rather than a selective amylin receptor agonist.
What is the CagriSema program?
CagriSema is a fixed-ratio combination of Cagrilintide and Semaglutide under investigation by Novo Nordisk in Phase 3 clinical trials. It represents the first investigational combination of a GLP-1 receptor agonist and a DACRA amylin analog in a single formulation. Research laboratories use individual Cagrilintide and Semaglutide compounds to study receptor pathway interactions independently from the fixed-ratio combination.
What purity is your Cagrilintide?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. Cagrilintide is not approved by the FDA for any indication. This product is for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications of any kind.
What other compounds does Nextday Peptides carry?
We also carry Retatrutide GLP-3, Tirzepatide GLP-2T, Semaglutide GLP-1, and MOTS-C. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not FDA approved for any indication • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
